INTRODUCTION
============

Numerous studies over the past 30 years have described a wide variety of circadian and sleep-wake cycle aberrations which occur in aging and neurodegenerative diseases ([@B29]; [@B65]). Many behavioral and physiologic processes oscillate with a 24 h period, including sleep--wake, activity, body temperature, blood pressure, and hormone secretion. These circadian rhythms are frequently disrupted in patients with neurodegenerative disease, including Alzheimer disease (AD), Parkinson disease (PD), Huntington disease (HD). Systemic circadian rhythms in mice and humans are maintained via the function of the body's master clock in the suprachiasmatic nucleus (SCN), which receives input from the retina and synchronizes oscillations in peripheral organs to the light:dark cycle. On a cellular level, circadian rhythms are generated by a transcriptional--translational feedback loop consisting of the bHLH/PAS transcription factors BMAL1 and CLOCK, which heterodimerize and drive transcription of many genes, including their own negative feedback repressors, including PERIOD (Per) and CRYPTOCHROME (Cry) and REVERB genes, which repress BMAL1/CLOCK-mediated transcription ([@B47]). This transcriptional machinery, which we will refer to herein as the core circadian clock, is present in most cells in the body, including neurons and astrocytes in the SCN and throughout the brain. The core circadian clock regulates the circadian expression of thousands of genes in a tissue-specific manner, and is a major regulator of cellular metabolism, stress response, and many other functions ([@B5]; [@B20]). While whole-organism rhythms are known to be disrupted in many neurodegenerative diseases, far less information exists regarding specific alterations in clock protein expression and function in these conditions. Furthermore, it remains unclear if or how circadian disruption might influence the neurodegenerative process itself, or if the core clock represents a reasonable therapeutic target for the treatment or prevention of neurodegeneration. We will focus on these issues in this review.

PART 1: IS THERE EVIDENCE OF CORE CIRCADIAN CLOCK DYSFUNCTION IN NEURODEGENERATIVE DISEASES?
============================================================================================

In AD, both sleep and circadian dysfunction are commonly reported. While sleep disturbances in AD are beyond the scope of this discussion and have been reviewed elsewhere ([@B29]; [@B54]), it is important to mention that subtle sleep disturbances appear to occur early in the disease process and may predict amyloid-beta (Aβ) plaque pathology and precede subsequent development of clinical dementia ([@B30]; [@B42]; [@B59]). Disrupted circadian rhythms in activity, physiologic parameters, and melatonin secretion have been reported in AD reported by several groups ([@B68]; [@B58]; [@B25]; [@B69]; [@B27]; [@B17]). A proposed mechanism of circadian dysfunction in AD is degeneration of the SCN, as loss of critical vasopressin and vasoactive intestinal peptide (VIP)-expressing neurons in this region has been reported in AD patients ([@B61]; [@B73]; [@B22]). Transcriptional analysis of postmortem human brain tissue has revealed detectable oscillations in core clock genes in various brain regions based on time of death, and shown that in AD brains the phase of oscillation is dysregulated between various regions ([@B10]; [@B43]). Rhythms in whole-genome DNA methylation could also be detected which appear to become less robust with age or in AD brains ([@B44]). Circadian oscillation of clock genes in the human pineal gland was disrupted even at very early pathological stages of AD, mirroring loss of rhythmic melatonin secretion in AD patients ([@B58]; [@B69]). Thus, in human AD there is evidence of disturbed rhythms of clock gene expression which appear to begin early in the disease course.

Animal models of AD also exhibit disturbances of behavioral and physiologic circadian rhythms. In mice, these disturbances appear to correlate with the degree of amyloid plaque burden, and can in some cases be rescued with anti-Aβ immunotherapy, suggesting that aggregated forms of Aβ might disrupt clock mechanisms ([@B67]; [@B60]; [@B19]; [@B56]). However, while one study described damped expression of *Per2* in the SCN of APP-PS1 transgenic mice ([@B19]), more detailed molecular analysis of clock gene function in AD mouse models is lacking. In *Drosophila*, two groups have found that pan-neuronal expression of arctic mutant human Aβ causes marked degradation of behavioral circadian rhythms, despite preserved clock gene oscillation in the central pacemaker cells ([@B13]; [@B45]). [@B13] found that restricted Aβ expression in central clock (PDF) neurons did not disrupt clock gene oscillation or cause behavioral arrhythmicity, which Aβ expression in glia surrounding the clock neurons did both. Thus, in flies, Aβ does not directly disrupt clock gene function in the central pacemaker, but acts more peripherally (and perhaps on glia) to disrupt behavioral rhythms. While the biological relevance of this fly models of Aβ toxicity to humans is debatable, these findings provide leads for further research in mammalian models.

In the case of PD, the second most common age-related neurodegenerative condition, there is ample evidence of disrupted circadian rhythms and sleep--wake disturbance in humans and mouse models ([@B64]). PD patients exhibit progressive disruption of activity rhythms ([@B51]), as well as damped circadian oscillation of both melatonin release and *Bmal1* expression in peripheral blood monocytes ([@B9]; [@B8]; [@B66]). Fly and mouse models of PD which expresses mutant human α-synuclein, a protein implicated in PD pathogenesis, develop behavioral circadian disruption early in its disease course ([@B23]; [@B38]). Synuclein transgenic mice display normal *Per2* oscillation in the SCN, but have damped electrical output from the SCN, again suggesting disordered SCN function or synchrony ([@B38]).

Huntington disease, unlike AD and PD, is an autosomal disorder caused by trinucleotide expansion within the *huntingtin* gene. Neurodegeneration occurs earlier in HD patients and initially involves the basal ganglia. Sleep and circadian rhythm dysfunction are common in HD ([@B49]; [@B3]), though there is a paucity of studies on clock gene expression and function in human HD. Several mouse models of HD, which express expanded human *huntingtin*, develop pronounced impairment in behavioral circadian rhythms ([@B49]; [@B39]). The R6/2 line exhibits behavioral arrhythmicity as well as dysregulated clock gene oscillation *in vivo* in the liver and SCN ([@B49]; [@B46]). Interestingly, clock gene oscillation appears to be normal in liver or SCN explants from R6/2 mice, suggesting that some other aspect of the internal milieu of the R6/2 mouse is causing arrhythmicity *in vivo* ([@B52]; [@B46]). In another HD mouse line (BACHD) the rhythmicity of electrical output of the SCN was disrupted, while the oscillation of *Per2* transcription was grossly intact ([@B39]). These findings suggest support the idea that dysfunction of the neural networks within the SCN, rather than the cell-intrinsic clock gene oscillation, underlies circadian impairment in HD model mice. Accordingly, decreased expression of the neuropeptide VIP and the VIP receptor VPAC2, which are critical for SCN function ([@B2]), was also observed in R6/2 mice ([@B21]). It appears that in HD mice, disrupted peripheral rhythms may adversely impact SCN function, leading to further systemic circadian arrhythmicity, though the details of this mechanism are still being explored.

PART 2: IS THERE EVIDENCE THAT CLOCK DISRUPTION EXACERBATES NEURODEGENERATION?
==============================================================================

While circadian disturbances in aging and neurodegenerative diseases have been duly noted, a key question is whether these disturbances influence disease pathology. This question is much more difficult to examine, and has received significantly less attention. In *Drosophila*, levels of oxidative stress markers, as well as cellular content of the critical antioxidant glutathione show circadian oscillation which is dependent on the clock gene Period (*Per*, [@B35]; [@B7]). *Per* deletion exacerbates oxidative injury and shortens lifespan in *Drosophila* ([@B35], [@B36]). Disruption of clock function via *Per* deletion also accelerates neurodegeneration in flies bearing a carbonyl reductase mutation which causes oxidative injury to neurons ([@B37]). However, in fly models of Aβ pathology which express different human Aβ isoforms, *Per* deletion did not impact neurodegeneration or behavior, though lifespan was decreased. Conversely, levels of Cryptochrome (*Cry*), which serves as a light-responsive modulator of clock function in *Drosophila*, decline in parallel with damped circadian rhythms in old flies, while *Cry* overexpression restores robust rhythms and enhances lifespan ([@B55]). Thus, the clock genes *Per* and *Cry* clearly appear to contribute to regulation of brain aging and neurodegeneration in fly models.

In mice, evidence linking circadian dysfunction and neurodegeneration is emerging. Chronic disruption of circadian rhythms in mice via housing in 20:4 light:dark conditions leads to decreased neuronal dendritic arborization and cognitive deficits, demonstrating that disturbed circadian rhythms have negative implications for the brain, though the exact degree of clock gene dysregulation and the role of other factors such as stress are unknown ([@B32]). Accordingly, studies in rats and hamsters have demonstrated cognitive impairment and decreased hippocampal neurogenesis following chronic "jet lag" protocols, during which circadian rhythms are disrupted by frequent shifting of the light:dark cycle ([@B24]; [@B34]). Mechanistically, RevErbα-mediated regulation of fatty acid binding protein 7 (*Fabp7*), both of which are strongly controlled by the core clock, has been implicated in neurogenesis ([@B57]). Similarly, RevErbα shows dynamic activity-dependent regulation in the dendrites of hippocampal neurons and interacts with oligophrenin-1, a regulator of dendritic spines ([@B63]). In a mouse model of AD, Aβ levels in the brain interstitial fluid show pronounced circadian oscillation ([@B31]), though it unclear if this is a direct effect of the sleep--wake cycle or may be more directly clock-mediated.

In order to gain some appreciation of the role of clock genes in maintaining brain homeostasis, our group performed functional and neuropathologic analysis of mice with global deletion of *Bmal1*. *Bmal1* knockout (KO) mice developed marked astrogliosis which was evident by 2 months of age and progressed to involve the entirety of the cortex, striatum, and hippocampus ([@B50]). These mice also had increased levels of oxidative damage in the cortex, and exhibited spontaneous degeneration of presynaptic terminals and diminished cortical functional connectivity. We found a similar phenotype in *Clock;Npas2* double KO mice, which like *Bmal1* KOs have completely disabled core clock transcriptional function ([@B18]), but not in *Per1/Per2* double mutant mice, which are arrhythmic but have intact core clock-mediated transcription ([@B4]). We subsequently generated brain-specific *Bmal1* KO mice which have preserved SCN *Bmal1* expression and intact systemic circadian activity and sleep rhythms, but disrupted BMAL1-mediated transcription in cortical, striatal, and hippocampal neurons and astrocytes. These mice also developed severe astrogliosis, suggesting that positive-limb core clock function is required locally in neurons and/or astrocytes to prevent pathology, independent of the SCN or sleep--wake cycle ([@B50]). Finally, we found that neurodegeneration induced by the mitochondrial complex II inhibitor 3-nitropropionic acid, which has been used to model HD ([@B6]), was exacerbated in *Bmal1* hemizygous mice, which have intact systemic rhythms but only half the normal level of BMAL1 protein expression in the brain. Thus, it appears that the core clock transcriptional machinery plays a critical role in protecting the brain from oxidative injury, and that this function is not entirely dictated by systemic circadian rhythms. Accordingly, we found that *Bmal1* directly regulates the transcription of several important redox defense genes in the brain, including *Nqo1* and *Aldh2*. We are currently working to identify novel mechanisms by which the core clock mediates neuroprotection or neurodegeneration, and to understand the relative importance of systemic circadian rhythms and clock gene oscillation versus static transcriptional function in this process.

Conversely, the effect of improving circadian function on pathology in a mouse model of neurologic disease has been demonstrated, at least initially. In the aforementioned R6/2 mouse model of HD, pharmacologic induction of rhythmic sleep normalized *Per2* oscillation in the SCN and lead to improvements in cognition ([@B52]; [@B53]). Furthermore, when food was provided to these mice only during a strategic window in the circadian cycle, rhythms in behavior were restored and metabolic abnormalities in these mice improved, suggesting that synchronizing the food-entrainable oscillator could overcome the circadian defect. Thus, correcting peripheral rhythms by imposing circadian sleep or feeding schedules can mitigate cognitive impairment in a mouse model of HD ([@B46]). The application of these methods, or more specific molecular targeting of the core clock or its outputs, now needs to be evaluated in other animal models of neurodegeneration.

Human data demonstrating a contributory effect of circadian disruption to neurodegeneration is scarce, though several encouraging findings have emerged. Two observational studies examining young female flight attendants who routinely flew across multiple time zones found that the group that those afforded shorter recovery time between cross-time zone flights (who thus experienced more severe circadian disruption) had higher cortisol levels, smaller temporal lobe volumes on MRI, and performed more poorly on hippocampal-based cognitive testing than ground crew members or other flight attendants with less severe jet lag exposure ([@B16]; [@B15]). In the field of AD, a small amount of human data now also exists which supports a role for circadian disruption in disease pathogenesis. Three separate genetic polymorphism in the *Clock* gene have been linked to increased risk of AD in Han Chinese populations ([@B11],[@B12]; [@B71]), though these findings have not been reported by other large AD genetics consortiums. An epidemiologic study of daily activity data from of over 1,200 initially cognitively-normal older women demonstrated that diminished circadian rhythm amplitude, robustness, or phase delay were associated with increased risk of developing dementia during the 5 year follow-up period ([@B62]). On a more mechanistic level, circadian oscillations in the level of the Aβ in cerebrospinal fluid of older adults has been described and suggest possible regulation of Aβ metabolism by the circadian clock, though it does not demonstrate a clear role for these oscillations in the disease process ([@B31]; [@B28]). Further research into circadian function in prodromal AD and other neurodegenerative disease, and how this relates to disease risk or progression is needed.

CONCLUSIONS AND THERAPEUTIC PERSPECTIVES
========================================

Taken in total, there is promising early data but not iron-clad proof that circadian clock disruption contributes to the pathogenesis of age-related neurodegenerative diseases. Two major challenges in this area are apparent. First, distinguishing the specific effects of alterations in sleep from those of the circadian clock is difficult but necessary. Activity data (actigraphy) in humans is often used as a biomarker of sleep or circadian rhythms, and the two processes are often lumped together, obscuring specific conclusions about either. Of further concern is the fact that disrupting sleep impacts core clock protein function ([@B48]), while deleting clock genes also alters sleep ([@B41]). Disentangling these two processes is important if we hope to identify specific downstream pharmacologic targets from either pathway to treat or prevent neurodegenerative diseases.

The second major challenge involves distinguishing the specific importance of circadian oscillation versus the "static" function of clock proteins in the brain. While circadian oscillations are observed in thousands of transcripts in many tissues, including the brain, the physiological relevance of these oscillations remains in many cases unclear ([@B72]). Clock proteins exert various functions in cells, some of which may have less dependence on these oscillations. Ultimately, the function of clock proteins is never completely disengaged from their oscillation, as the BMAL1/CLOCK DNA binding shows clear circadian variation ([@B33]), but the relative importance of rhythmic versus static function remains a key therapeutic question. If restoration of robust systemic oscillations is the therapeutic goal, then therapies might target the SCN. Vasopressin V1a and V1b, as well as VIP VPAC2 receptors, play critical roles in synchronizing SCN neurons and their response to phase shift, and thus might represent tractable therapeutic targets to optimize systemic rhythms ([@B2]; [@B1]; [@B40]; [@B70]). Behavioral manipulations such as imposed light:dark exposure, timed melatonin treatment, or rhythmic meal schedules might have shown promise in HD mouse models and might also be considered ([@B52]; [@B46]). Finally, novel small molecule modulators of clock oscillation are being developed which alter the period, amplitude, or frequency of SCN output ([@B26]; [@B14]). However, if bolstering clock gene expression outside the SCN is the more advantageous strategy, then a new set of therapies would need to be developed. In this case, downstream neuroprotective targets of the core clock would need to be identified and screening pursued to identify compounds or strategies which enhance core clock transcription of these protective downstream targets. Because the clock serves as an orchestrator of a multitude of biological processes, there is great potential for clock-targeted therapeutics to simultaneously ameliorate multiple pathologic aspects of complex neurodegenerative diseases. Thus, it is important to more fully understand the mechanisms by which the circadian clock regulates brain function and neurodegeneration, such that rational strategies to target the clock for neuroprotection can be devised.
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